<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04129281</url>
  </required_header>
  <id_info>
    <org_study_id>MITICA</org_study_id>
    <nct_id>NCT04129281</nct_id>
  </id_info>
  <brief_title>Active Surveillance Versus Surgery in Thyroid Papillary Microcarcinoma</brief_title>
  <acronym>MITICA</acronym>
  <official_title>Prospective Active Surveillance Versus Surgery in Thyroid Papillary Microcarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the outcome of two treatment approaches
      (immediate surgery or close follow-up) in patients with papillary thyroid microcarcinoma
      (mPTc) .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the outcome of two treatment approaches
      (immediate surgery or close follow-up) in patients with papillary thyroid microcarcinoma
      (mPTc) .

      A further objective is to identify events associated with high risk of local recurrence and
      distant metastases.

      Patients will be randomized to surgery or active surveillance. Patients who refuse the
      randomization process will be followed according to the treatment choice according to
      clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2019</start_date>
  <completion_date type="Anticipated">February 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 23, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized to surgery or active surveillance. Patients who refuse the randomization process will be followed according to the treatment choice according to clinical practice.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life in patient who received either surgery or follow up</measure>
    <time_frame>36 months</time_frame>
    <description>EORTC QLQ-C30, a quality of life questionnaires, composed by 30 items graded from1 (not at all) to 4 (very much) within 1 year from the diagnosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life in patient who received either surgery or follow up</measure>
    <time_frame>36 months</time_frame>
    <description>EORTC QLQ-C30, a quality of life questionnaires, composed by 30 items graded from1 (not at all) to 4 (very much) after 1 year from the diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the two strategies in terms of anxiety/depression</measure>
    <time_frame>36 months</time_frame>
    <description>Evaluate the number of patients developing anxiety/depression (Hospital Anxiety and Depression Scale) (HADS scale, Each item on the questionnaire is scored from 0-3 and) in the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the two strategies in terms of adverse events</measure>
    <time_frame>36 months</time_frame>
    <description>Evaluate the number of patients developing adverse events (CTCAE 5.0)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Papillary Microcarcinoma of the Thyroid</condition>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active surveillance</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Follow up</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Surgery acconding to clinical practice</description>
    <arm_group_label>Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;or =18

          -  Suspicious nodule &lt; or = or 13 mm in the maximum size of thyroid ultrasound (not older
             than 3 months after the screening visit)

          -  Cytology consistent with the TIR4 or TIR 5 class

          -  Sieric TSH in th standard range (with or without levo-tyroxin therapy)

          -  Normal string motility to fibrolaringoscopy

          -  Written informed consent

        Exclusion Criteria:

          -  Ultrasound evidence of suspicious lump located on the posterior side of the lobe close
             to neurogene structures

          -  Calcitonin increase above normal levels

          -  Clinical or instrumental evidence of locoregional lymph node metastases (central or
             laterocervical compartment) or remote

          -  any Contraindications to surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luciano Pezzullo</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luciano Pezzullo</last_name>
    <phone>+39 0815903462</phone>
    <email>l.pezzullo@istitutotumori.na.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clorinda Schettino</last_name>
    <phone>+39 081 590 1791</phone>
    <email>c.schettino@istitutotumori.na.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istitute Nazionale Tumori - Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>October 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>October 17, 2019</last_update_submitted>
  <last_update_submitted_qc>October 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Papillary Microcarcinoma of the Thyroid</keyword>
  <keyword>Surgery</keyword>
  <keyword>Outcome</keyword>
  <keyword>Follow up</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Papillary</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

